ArticleCureus2026
The Mesenteric Masquerader: A Rare Primary Neuroendocrine Tumor of the Mesentery.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Primary neuroendocrine tumors (NETs) arising exclusively within the mesentery, without an identifiable gastrointestinal or pancreatic primary, are exceedingly rare and often present with non-specific symptoms, making preoperative diagnosis challenging. We report the case of an 80-year-old female who presented with a six-month history of right-sided abdominal pain and a palpable abdominal mass. Contrast-enhanced computed tomography of the abdomen revealed a well-defined soft tissue lesion measuring 7.1 × 4.4 × 5.3 cm in the right iliac fossa mesentery, with vascular supply from the superior mesenteric artery. The mass was successfully excised laparoscopically en masse. Histopathological examination demonstrated a WHO Grade I well-differentiated NET with lymphovascular invasion and negative resection margins. Immunohistochemistry showed positivity for pan-cytokeratin, synaptophysin, chromogranin, INSM1, and CD56. This case highlights the diagnostic challenge of primary mesenteric NETs and supports surgical resection as the definitive management. Careful postoperative surveillance is warranted due to the potential for recurrence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.